Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

139.70CHF
4:09pm GMT
Change (% chg)

CHF-0.90 (-0.64%)
Prev Close
CHF140.60
Open
CHF140.70
Day's High
CHF141.70
Day's Low
CHF139.70
Volume
10,688
Avg. Vol
21,495
52-wk High
CHF181.80
52-wk Low
CHF129.20

Select another date:

Wed, Nov 1 2017

BRIEF-Cosmo Pharmaceuticals: update on commercialization of Rifamycin SV MMX

* ‍ITS PARTNER DR. FALK PHARMA HAS FILED FOR MARKETING AUTHORIZATION OF RIFAFALK 200MG IN GERMANY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals: update on lawsuit against patent infringement on Uceris‍​

* DISTRICT OF DELAWARE HAS RULED NON-INFRINGEMENT OF ACTAVIS ANDA PRODUCT FOR GENERIC VERSION OF VALEANT’S UCERIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals and Fujifilm establish distribution agreement for Eleview for Europe & South Africa

* WITH FUJIFILM ESTABLISH DISTRIBUTION AGREEMENT FOR ELEVIEW® FOR EUROPE & SOUTH AFRICA​

BRIEF-Cosmo Pharmaceuticals: FDA grants QIDP and fast track designations for Aemcolo​

* ‍FDA GRANTS COSMO PHARMACEUTICALS BOTH QIDP AND FAST TRACK DESIGNATIONS FOR AEMCOLO​ Source text - http://bit.ly/2zvcXIc Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals says ‍FDA accepts new drug application submission for methylene blue mmx​

* ‍FDA ACCEPTS NEW DRUG APPLICATION SUBMISSION FOR COSMO PHARMACEUTICAL'S METHYLENE BLUE MMX(TM)​

BRIEF-Cosmo Pharmaceuticals and Olympus America establish co-promotion agreement for Eleview

* COSMO PHARMACEUTICALS AND OLYMPUS AMERICA INC. ESTABLISH CO-PROMOTION AGREEMENT FOR ELEVIEW(TM) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals swings to H1 ‍operating loss of EUR 8.4 mln

* ‍H1 REVENUE OF EUR 31.8 MILLION COMPARED TO EUR 31.6 MILLION IN PRIOR YEAR​

BRIEF-Cosmo announces European approval of Qolotag for sigmoidoscopies in IBD patients

* COSMO PHARMACEUTICALS NV - COSMO ANNOUNCES EUROPEAN APPROVAL OF QOLOTAG® FOR SIGMOIDOSCOPIES IN IBD PATIENTS

BRIEF-Cosmo Pharmaceuticals submits to FDA new drug application for LuMeBlue‍​

* ANNOUNCES SUBMISSION TO FDA OF NEW DRUG APPLICATION FOR LUMEBLUE‍​ Source text - http://bit.ly/2uoLUPd Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo says Remimazolam successfully concludes late-stage trial

* Says Remimazolam successfully concludes phase iii clinical trial for procedural sedation in bronchoscopy

Select another date: